How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses
Tiago Reis Marques, Stephen Z Levine, Avi Reichenberg, Rene Kahn, Eske M Derks, Wolfgang W Fleischhacker, Jonathan Rabinowitz, Shitij Kapur
European Neuropsychopharmacology | ELSEVIER | Published : 2014
Awarded by NIMH
Awarded by Medical Research Council
Data used in the preparation of this article were obtained from the limited access datasets (version 1.7) distributed from the NIH-supported "Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia" (CATIE-Sz). This is a multisite clinical trial of persons with schizophrenia comparing the effectiveness of randomly assigned medication treatment. The study was supported by NIMH Contract #N01MH90001 to the University of North Carolina at Chapel Hill. The Clinical Trials.gov identifier is NCT00014001. This presentation reflects the views of the authors and may not reflect the opinions or views of the CATIE-Sz Study Investigators or the NIH.The primary funding agency for EUFEST was the European Schizophrenia Foundation supported by AstraZeneca, Pfizer and Sanofi-Aventis. We acknowledge with thanks Johnson & Johnson for providing us with data in part of this manuscript. This article may or may not reflect their views. The research was in part financially supported by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Tiago Reis Marques research is supported by NARSAD.